Aptar inks deal to target Chinese injectable drug delivery fieldnews2021-08-02T12:38:37+00:00August 2nd, 2021|Fierce Pharma|
Fresh from $225M IPO, atai founds nose-to-brain delivery startupnews2021-08-02T12:35:02+00:00August 2nd, 2021|Fierce Pharma|
AstraZeneca nabs FDA nod to challenge GSK’s Benlysta with first-in-class lupus drug Saphnelonews2021-08-02T12:00:55+00:00August 2nd, 2021|Fierce Pharma|
With expanded FDA nod, Regeneron’s COVID-19 antibody drug can help the immunocompromisednews2021-07-30T18:05:23+00:00July 30th, 2021|Fierce Pharma|
AbbVie’s post-Humira stalwarts Skyrizi, Rinvoq performing exactly as hoped, CEO saysnews2021-07-30T15:38:32+00:00July 30th, 2021|Fierce Pharma|
BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa winnews2021-07-30T15:32:05+00:00July 30th, 2021|Fierce Pharma|
U.K. slaps Advanz Pharma with $140M fine after 1,110% price hike on ‘crucial’ thyroid drugnews2021-07-30T15:27:40+00:00July 30th, 2021|Fierce Pharma|
From accelerated approval to the TV airwaves: GBT debuts first DTC campaign for sickle cell med Oxbrytanews2021-07-30T15:07:13+00:00July 30th, 2021|Fierce Pharma|
Senate takes aim at pharma’s patent schemes, pay-for-delay deals in renewed drug pricing crackdownnews2021-07-30T14:47:46+00:00July 30th, 2021|Fierce Pharma|
The curious case of Eohilia: Takeda drug hit with mysterious FDA delay as company leans on launches for growthnews2021-07-30T13:41:00+00:00July 30th, 2021|Fierce Pharma|
